ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?

Neurooncol Adv · 2019 · PMC7213217

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Depatux-M in combination with temozolomide showed a trend towards improved survival times compared to temozolomide/lomustine alone, with patients relapsing more than 4 months after the last adjuvant temozolomide cycle deriving the greatest benefit.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.